Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.

Breast Cancer Clinical Trial

Official title:

Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05649072
• Other study ID #: 2022-0329
• Secondary ID: NCI-2022-10036
• Status: Recruiting
• Phase: N/A
• Start date: November 18, 2022
• Est. completion date: February 2, 2027

Study information

• Verified date: June 2024
• Source: M.D. Anderson Cancer Center
• Contact: Arun Banu, MD
• Phone: (713) 792-2817
• Email: barun[@]mdanderson.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Identifying women at risk for hereditary cancer potentiates prevention, early detection or personalised treatment against cancer. We using mobile mammography units will provide genetic sceening and testing services to underserved women coming for thier mammograms to these units.

Description:

Objectives:

1. To identify underserved women at risk for hereditary breast and colorectal cancers and would be eligible for standard of care genetic counseling and testing using national screening guidelines.

2. To provide education to providers and patients regarding hereditary cancers using previously IRB approved educational material and short video.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1000
• Est. completion date: February 2, 2027
• Est. primary completion date: February 2, 2027
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Any woman scheduled at Project VALET mammography screening mobile units will be eligible for this study.

Exclusion Criteria:

Related Conditions & MeSH terms

• Breast Cancer
• Colorectal Cancer
• Ovarian Cancer

Intervention

Behavioral:
• Genetic Testing and Counseling
Participants will be asked to collect a saliva sample for hereditary cancer and genetic testing
• Screening Form
Participant will be answering demographic details

Locations

Country	Name	City	State
United States	M D Anderson Cancer Center	Houston	Texas

Sponsors (2)

Lead Sponsor	Collaborator
M.D. Anderson Cancer Center	Community Outreach and Engagement Fund for Underserved Texans

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To identify underserved women at risk for hereditary breast and colorectal cancers eligible for standard-of-care genetic counseling using national screening guidelines.		through study completion; an average of 1 year.

External Links

•   M D Anderson Cancer Center